bioAffinity Technologies Reports Director Changes and Bylaw Amendments
Ticker: BIAFW · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1712762
Sentiment: neutral
Topics: corporate-governance, leadership-change, bylaws
Related Tickers: BIAF
TL;DR
BIAF board shakeup, bylaws changed, new execs appointed - big governance moves happening.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on June 4, 2024, reporting several key events. These include the departure of directors, election of new directors, appointment of officers, and changes to compensatory arrangements. The company also amended its articles of incorporation and bylaws, and submitted matters to a vote of security holders. Financial statements and exhibits were also filed.
Why It Matters
This filing indicates significant corporate governance changes, including leadership transitions and potential shifts in company strategy or operations due to bylaw amendments.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with amendments to governing documents, can signal instability or strategic shifts that may impact the company's future performance.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
FAQ
Who has departed from the board of directors or as an officer?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in the provided text.
Were new directors elected or officers appointed?
Yes, the filing explicitly states the election of directors and the appointment of certain officers.
What specific amendments were made to the articles of incorporation or bylaws?
The filing notes amendments to the articles of incorporation or bylaws, but the specific details of these amendments are not provided in the excerpt.
Were any matters submitted to a vote of security holders?
Yes, the filing confirms the submission of matters to a vote of security holders.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 1,223 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-06-05 16:10:32
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 78KB
- ex3-1.htm (EX-3.1) — 11KB
- ex10-1.htm (EX-10.1) — 297KB
- 0001493152-24-022738.txt ( ) — 664KB
- biaf-20240604.xsd (EX-101.SCH) — 4KB
- biaf-20240604_def.xml (EX-101.DEF) — 26KB
- biaf-20240604_lab.xml (EX-101.LAB) — 36KB
- biaf-20240604_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. bioAffinity Technologies, Inc. By: /s/ Maria Zannes Maria Zannes President and Chief Executive Officer Dated: June 5, 2024